Why the study?
Recent evidence supports repurposing colchicine across multiple cardiovascular conditions, including pericarditis, coronary artery disease, and atrial fibrillation.
Does colchicine improve outcomes in patients with cardiovascular conditions such as coronary artery disease, pericarditis, and atrial fibrillation?
Does colchicine improve outcomes in patients with cardiovascular conditions such as coronary artery disease, pericarditis, and atrial fibrillation?
Colchicine is an effective repurposed anti-inflammatory therapy for multiple cardiovascular conditions, including pericarditis, coronary artery disease, and atrial fibrillation.
May support colchicine in pericarditis and CAD; leaves open confirmatory RCTs for AF and broader use.
plant and is routinely used because of its broad anti-inflammatory properties to treat gout and familial Mediterranean fever. Colchicine has shown efficacy in various clinical settings in which inflammation is a key component, and it has become first-line therapy for acute and recurrent pericarditis. Two landmark clinical trials have recently shown that colchicine significantly improves cardiovascular outcomes on background statin and antiplatelet therapy in patients with coronary artery disease, supporting its role for the prevention of atherothrombotic events. Favorable results have also emerged in atrial fibrillation. We herein briefly review the most recent data related to the multiple cardiovascular conditions for which colchicine has been successfully repurposed.
No takes yet. Share an insight, caveat, or question.
Bouabdallaoui et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: